FindTrial
Sign In

A Clinical trial to study the effect of Nrupavallabha taila nasya followed by Raktachandanadi Udvartana in the management of Vyanga (Melasma)

A Randomised Controlled Clinical Study to evaluate efficacy of Nrupavallabha taila Marsha Nasya followed by Raktachandanadi Udvartana in the management of Vyanga With Special Reference to Melasma. - NIL

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
CTRI
Registry ID
CTRI/2024/07/070250
Enrollment
64
Registered
2024-07-09
Start date
Unknown
Completion date
Unknown
Last updated
2024-07-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: L00-L99- Diseases of the skin and subcutaneous tissue Health Condition 2: L599- Disorder of the skin and subcutaneous tissue related to radiation, unspecified Health Condition 3: L578- Other skin changes due to chronicexposure to nonionizing radiation

Interventions

None listed

Sponsors

RA Podar Medical (Ayu) College, Worli, Mumbai
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: 1. Patients fit for Nasya Karma according to Classics. 2. Patients having signs and symptoms of Vyanga like mandalakara, niruja, tanu, and shyav-varni mandala on face with 0.5 - 5 cm. 3. Patients having age group 20 - 60 yrs. 4. Patients of both genders. 5. Chronicity less than 5 years.

Exclusion criteria

Exclusion criteria: 1. Pregnant and lactating women. 2. Post inflammatory hyperpigmentation, post acne hyperpigmentation. 3. Vyanga caused since birth like Nevus of ota. 4. Patients using depigmentation agents. 5. Patient having Acne vulgaris. 6. Patient having history of HIV /AIDS.

Design outcomes

Primary

MeasureTime frame
1.There is reduction in MASI (Melasma Area Severity Index) Score indicating reduced Melasma. 2.There is reduction in Fitzpatrick scale score indicating reduced Color Melasma.Timepoint: Day 1 and Day 36—

Secondary

MeasureTime frame
Assessment of no.of Mandala (circular lesions), Rukshata (Dryness), Size (diameter)Timepoint: Day 1 and Day 36—

Countries

India

Contacts

Public ContactDR KAJAL PRAMODRAO DAHAKE

M A Podar Medical (Ayu) Hospital, Worli

seemabahatkar@gmail.com9881900560

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026